Rezolute to initiate a pivotal phase 3 study of rz358 in participants 3 months of age and older with congenital hyperinsulinism

Study to be initiated in europe and other ex-us geographies in q4 2023, with topline results expected 1h 2025 conference call scheduled today at 4:30 p.m. et redwood city, calif.

RZLT Ratings Summary

RZLT Quant Ranking